EUVIMEDEUVIMED entdecken
Crossref

Macrophage‐Mediated Delivery of miR‐34a‐5p‐Nanoparticles for Pathogenic Inhibition of Kaposi's Sarcoma‐Associated Herpesvirus

Lixia Yao, Qing Zhang, Xingxing Gao, Fangling Li, Lei Zhang, Jinli Zhang, Wenyi Gu, Xiaohua Tan iD, Dongmei Li iD, Dongdong Cao, Yuanming Pan

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Lixia Yao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Xinjiang Endemic and Ethnic Diseases/NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, School…. Hauptthemen laut MEDLINE: MicroRNAs, Herpesvirus 8, Human, Macrophages, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Foundation of China, the Shihezi University interdisciplinary research project, the Zhejiang Provincial….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaposi's sarcoma‐associated herpesvirus (KSHV) has been demonstrated to trigger a variety of malignant neoplasms, however, there are currently no targeted pharmaceutical interventions available. MicroRNA(miRNA)‐based antiviral and tumor therapies are frequently utilized, yet the challenges of cellular uptake and susceptibility to degradation underscore the necessity for a delivery system that can effectively combat KSHV. Nonetheless, despite the efficacy of nanocarriers in delivering drugs into cells, they continue to encounter challenges in penetrating the brain. In this study, a macrophage inflammation model was developed to enhance the delivery of miR‐34a‐5p loaded by folic acid‐modified β‐cyclodextrin grafted polyethyleneimine (β‐CD‐PEI‐FA) nanocomposites, based on FA targeted to folate receptors on the surface of macrophages and tumor cells. Both in vivo and in vitro safety evaluations of the nanocarriers were performed, which confirmed the exceptional biocompatibility. Assays involving the coculture of induced nanodrug‐loaded macrophages and KSHV‐positive cells demonstrated the efficient delivery of miR‐34a‐5p into KSHV‐positive cells through macrophages. This delivery led to the inhibition of the proliferation and cell cycle of cocultured KSHV‐positive cells, as well as a significant reduction in the expression of KSHV pathogenic genes RTA and v‐GPCR. Notably, fluorescence imaging of organs revealed the in vivo delivery of nanocomposites into brain tissues, including tumors. Furthermore, immunohistochemistry analysis revealed increased macrophages infiltration in both tumors and brain tissues in xenograft mice. In conclusion, our study presents a pioneering strategy employing macrophages as carriers for delivering β‐CD‐PEI‐FA/miR‐34a‐5p nanocomplexes in anti‐KSHV therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsHerpesvirus 8, HumanMacrophagesNanoparticlesAntiviral AgentsAnimalsHumansMiceDrug CarriersNanocompositesPolyethyleneimine

Stichwörter der Autor:innen

Blood–brain barrierKSHVMacrophageNanocarrierscoculturemiR‐34a‐5p

Substanzen

MicroRNAsMIRN34 microRNA, humanDrug CarriersAntiviral AgentsPolyethyleneimine

Autor:innen und Institutionen

  • Key Laboratory of Xinjiang Endemic and Ethnic Diseases/NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, School of Medicine, Shihezi University, Shihezi, Xinjiang, China.
  • The First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.
  • Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Corner College and Cooper Roads (Building 75), St Lucia, Brisbane, Australia.
  • School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, Tongzhou District, China.

ORCID-Profile: Xiaohua Tan, Dongmei Li

Förderung

  • This work was supported by the National Natural Science Foundation of China, the Shihezi University interdisciplinary research project, the Zhejiang Provincial…

Zitieren

APA

Yao, L., Zhang, Q., Gao, X., Li, F., Zhang, L., Zhang, J., Gu, W., Tan, X., Li, D., Cao, D., & Pan, Y. (2025). Macrophage‐Mediated Delivery of miR‐34a‐5p‐Nanoparticles for Pathogenic Inhibition of Kaposi's Sarcoma‐Associated Herpesvirus. Journal of Medical Virology. https://doi.org/10.1002/jmv.70298

Vancouver

Yao L, Zhang Q, Gao X, Li F, Zhang L, Zhang J, et al. Macrophage‐Mediated Delivery of miR‐34a‐5p‐Nanoparticles for Pathogenic Inhibition of Kaposi's Sarcoma‐Associated Herpesvirus. Journal of Medical Virology. 2025. doi:10.1002/jmv.70298

BibTeX
@article{Yao2025,
  author = {Yao, Lixia and Zhang, Qing and Gao, Xingxing and Li, Fangling and Zhang, Lei and Zhang, Jinli and Gu, Wenyi and Tan, Xiaohua and Li, Dongmei and Cao, Dongdong and Pan, Yuanming},
  title = {Macrophage‐Mediated Delivery of miR‐34a‐5p‐Nanoparticles for Pathogenic Inhibition of Kaposi's Sarcoma‐Associated Herpesvirus},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70298}
}
Kostenlos starten →